Nanomaterials-Based Photodynamic Therapy with Combined Treatment Improves Antitumor Efficacy Through Boosting Immunogenic Cell Death
Open Access
- 1 July 2021
- journal article
- review article
- Published by Taylor & Francis Ltd in International Journal of Nanomedicine
- Vol. ume 16, 4693-4712
- https://doi.org/10.2147/ijn.s314506
Abstract
Benefiting from the rapid development of nanotechnology, photodynamic therapy (PDT) is arising as a novel non-invasive clinical treatment for specific cancers, which exerts direct efficacy in destroying primary tumors by generating excessive cytotoxic reactive oxygen species (ROS). Notably, PDT-induced cell death is related to T cell-mediated antitumor immune responses through induction of immunogenic cell death (ICD). However, ICD elicited via PDT is not strong enough and is limited by immunosuppressive tumor microenvironment (ITM). Therefore, it is necessary to improve PDT efficacy through enhancing ICD with the combination of synergistic tumor therapies. Herein, the recent progress of nanomaterials-based PDT combined with chemotherapy, photothermal therapy, radiotherapy, and immunotherapy, employing ICD-boosted treatments is reviewed. An outlook about the future application in clinics of nanomaterials-based PDT strategies is also mentioned.Keywords
This publication has 126 references indexed in Scilit:
- Targeting ER stress induced apoptosis and inflammation in cancerCancer Letters, 2013
- A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell deathThe EMBO Journal, 2012
- The convergence of radiation and immunogenic cell death signaling pathwaysFrontiers in Oncology, 2012
- Photodynamic therapy of cancer: An updateCA: A Cancer Journal for Clinicians, 2011
- Adjuvant Therapy With Agonistic Antibodies to CD134 (OX40) Increases Local Control After Surgical or Radiation Therapy of Cancer in MiceJournal of Immunotherapy, 2010
- Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapyEmerging Therapeutic Targets, 2009
- OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosisThe Journal of Experimental Medicine, 2009
- Molecular characteristics of immunogenic cancer cell deathCell Death & Differentiation, 2007
- Caspase-dependent immunogenicity of doxorubicin-induced tumor cell deathThe Journal of Experimental Medicine, 2005
- Cancer treatment by photodynamic therapy combined with adoptive immunotherapy using genetically altered natural killer cell lineInternational Journal of Cancer, 2001